
Who can be treated with AMONDYS 45 (casimersen)?
AMONDYS 45 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 45.
This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.
Know your mutation.
If you haven’t already done so, get a genetic test to identify your child’s genetic mutation; your doctor or a genetic counselor can interpret the results to determine if the mutation is one that an estimated 9% of people with DMD have that is amenable to treatment with AMONDYS 45. Genetic test results may also help your doctor make other disease management decisions.


Understand test results.
When your child’s test results come back, it’s sometimes confusing to know what you’re reading. We’ll break it down and provide information you can use to talk to your child’s doctor about eligibility for AMONDYS 45.

Explore our Doctor Discussion Guide
It can be a challenge to remember all the information you want to when talking with your doctor. Utilize our helpful guide for information on what to ask during an appointment.
